semaglutide compounding news november 2025 Novo cuts GLP-1 prices 70%, but revenue could grow in 2026 Semaglutide injections will no longer

Weight loss affects disease activity and treatment response in inflammatory rheumatic diseases

Injectable GLP-1s may be more suitable for: Patients aiming for the maximum possible reduction in body weight, those with co-existing conditions like heart disease or chronic kidney disease (due to specific FDA approvals for Ozempic), or those who prefer a simple weekly medication schedule

Ready for convenient health solutions

But the tirzepatide shortage was declared resolved in December 2024, and the semaglutide shortage was declared resolved in February 2025

Thyroid C-cell effects: A class signal from animal studies exists for GLP-1 receptor agonists

Health Canadas classification of peptides depends on intended use, marketing claims, and manufacturing standards